Circulating VE-cadherin as a predictive marker of sensitivity or resistance to anti-tumoral treatment

摘要

The application relates to improved means for the detection of soluble protein(s), such as soluble angiogenesis-related protein(s), more particularly circulating VE-cadherin. These means notably comprise the dilution of the fluid sample (e.g., serum or plasma sample), before submitting it to protein detection. Said dilution is advantageously diluted in a surfactant-containing solution. The improved means of the invention enabled to determine that circulating VE-cadherin is a reliable prognostic marker of the sensitivity or resistance to anti-tumoral treatment. It is believed that prior art sVE-cadherin detection means did not enable such determination.